IP Library Granted Patent US 7,799,771
Granted Patent B2
US 7,799,771 · App. 11/154,704 · Granted Sep 21, 2010

Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,799,771
App. No.
11/154,704
Granted
Sep 21, 2010
Kind
B2
Abstract

A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-lower alkanoate, most preferably 17β-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed is a method for treating a human female in need of 17β-estradiol and a contraceptive method by oral administration of the pharmaceutical dosage unit and a method of preparing a pharmaceutical composition that may be used to form the pharmaceutical dosage unit of the invention.

Claims (7)

1. A pharmaceutical solid dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-acetate and a pharmaceutically acceptable carrier, wherein the percent moisture of said dosage unit is less than or equal to 5%, and the amount of 17β-estradiol-3-acetate is from about 0.1 to about 10 mg as estradiol equivalent.

2. The dosage unit according to claim 1 , further comprising one or more pharmaceutically acceptable inhibitors of hydrolysis wherein the inhibitors of hydrolysis are selected from the group consisting of acetic acid, formic acid, propionic acid, lactic acid and tartaric acid.

3. The dosage unit according to claim 1 , further comprising one or more additional steroids.

4. The dosage unit according to claim 3 , wherein said one or more steroids have progestational activity.

5. The dosage unit according to claim 1 , wherein the dosage unit is prepared by a granulation method.

6. The dosage unit according to claim 1 , wherein the dosage unit is a tablet, capsule, powder, lozenge, or troche.

7. The dosage unit according to claim 1 , wherein the dosage unit is a tablet or capsule.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2021
From: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
To: ALLERGAN THERAPEUTICS LLC
Reel/Frame 057605/0461 →
CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 22, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 045417/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 040183/0129 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT COMPANY LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026064/0607 →
RELEASE - REEL 023456, FRAME 0052 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
SECURITY AGREEMENT Recorded Nov 2, 2009
From: WARNER CHILCOTT COMPANY, LLC
To: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 023456/0052 →
CHANGE OF NAME Recorded Jun 18, 2009
From: WARNER CHILCOTT COMPANY, INC.
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 022835/0896 →